TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CSL ( (AU:CSL) ) has provided an announcement.
CSL Limited announced the issuance of 200 ordinary fully paid securities, effective November 5, 2025. This move indicates an ongoing strategy to enhance its capital structure, potentially impacting its market positioning and offering implications for stakeholders regarding the company’s financial strategies.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its work in plasma therapies, vaccines, and pharmaceuticals, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 1,351,815
Technical Sentiment Signal: Sell
Current Market Cap: A$85.87B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.